Suspended

International Registry for Severe Chronic Neutropenia

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected at a single point in time - Cross-sectional
DNA Samples
Who is being recruted

Cytopenia+8

+ Agranulocytosis

+ Hemic and Lymphatic Diseases

Over 3 Months
See all eligibility criteria
How is the trial designed

Other

Utilizing specific methods not covered by standard models in order to address unique research questions.
Observational
Study Start: June 1994
See protocol details

Summary

Principal SponsorNational Center for Research Resources (NCRR)
Study ContactAkiko Shimamura, MD, PhDMore contacts
Last updated: October 22, 2020
Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 1994

Actual date on which the first participant was enrolled.

PROTOCOL OUTLINE: Patients are treated by the referring physician as medically indicated. Clinical data are collected at baseline and then every 6 months.

Principal SponsorNational Center for Research Resources (NCRR)
Study ContactAkiko Shimamura, MD, PhDMore contacts
Last updated: October 22, 2020
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other

Some studies use unique or mixed approaches that don't fit standard categories. These may include innovative observational methods or studies tailored to specific research questions.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 3 Months

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

CytopeniaAgranulocytosisHemic and Lymphatic DiseasesLeukocyte DisordersLeukopeniaPathologic ProcessesPathological Conditions, Signs and SymptomsDisease AttributesHematologic DiseasesNeutropeniaRare Diseases

Criteria

Inclusion Criteria - Subjects are eligible for enrollment if they meet the following criteria: A confirmed diagnosis of severe chronic neutropenia based on documented absolute neutrophil counts of less than 0.5x109/L on at least three occasions in the three months prior to enrollment. For subjects with presumed cyclic neutropenia, documentation of at least two neutrophil cycles is preferred. Documentation should include the nadirs with neutrophil counts of less than 200 followed by a clear increase in the counts generally to at least 500 to 1000 followed by a second nadir, usually expected to occur at about three weeks after the first nadir, i.e., cycling with a three week periodicity. Documentation with at least six weeks of counts and two expected nadirs is preferred. Cases not showing clear oscillations will be categorized as congenital (if neutropenia or neutropenic complications appear to have occurred from birth) or idiopathic (if all symptoms in evidence point to an acquired disorder occurring after the first year of life). Bone marrow aspiration consistent with the diagnosis of congenital, cyclic or idiopathic neutropenia. In all of these conditions, it is expected that the marrow aspirate evaluation at the time of neutropenia will show a deficiency of mature neutrophils. An exception is myelokathexis, a condition with large accumulations of neutrophils with pycnotic nuclei in the marrow. Bone marrow aspirates may show some dyspoiesis of the neutrophil lineage, but abnormalities of erythropoiesis or platelet formation are, in general, inconsistent with the diagnosis of SCN. Normal cytogenetic evaluation. The only exception being cases of well documented severe congenital neutropenia with preferably previously documented normal cytogenetic evaluation will now be enrolled in the Registry at the time of evolution to leukemia. History of recurrent infections (i.e., severe mouth ulcers, gingivitis and sinusitis). Age greater than three months. Independent of hematological parameters, subjects with the following diagnoses may be included: Shwachman-Diamond syndrome (SDS), glycogen storage disease type 1b (GSD1b), Barth syndrome, and Cohen's syndrome. Subjects with moderately severe chronic neutropenia (i.e., ANC less than 1.0x109/L) and recurrent severe infections (i.e., deep tissue infections of subcutaneous areas, lungs, liver, etc.). Immune neutropenia with positive anti-neutrophil antibodies meeting criteria in 1, 3, 5 and 6. All SCN subjects originally enrolled in Amgen-sponsored SCN studies. Exclusion Criteria Neutropenia known to be drug induced Primary myelodysplasia Primary leukemia Aplastic anemia Known HIV disease Systemic autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus Chemotherapy-induced neutropenia (within the last 5 years)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

3 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 10 locations

Recruiting

Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center

Boston, United StatesOpen Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center in Google Maps
Recruiting

University of Massachusetts

Worcester, United States
Recruiting

University of Michigan

Ann Arbor, United States
Recruiting

St. Joseph's Children's Hospital

Paterson, United States
Suspended10 Study Centers